Search Our Scientific Publications & Authors

Diabetes Res Clin Pract 2022 Aug 2;191:110019. Epub 2022 Aug 2.

Division of Endocrinology, Department of Internal Medicine, Hospital Universitario San Ignacio, Faculty of Medicine, Pontificia Universidad Javeriana. Bogotá, Colombia. Electronic address:

Background: Current guidelines recommend insulin alone for in-hospital management of diabetes, but growing information suggests that new oral or injectable agents may be as effective and safe.

Methods: Systematic review and meta-analysis with evidence from randomized (RCT) and non-randomized (NRS) studies in PubMed, EMBASE and LILACS databases up to February 10, 2022, for studies including hospitalized type 2 diabetes patients, comparing dipeptidyl peptidase 4 inhibitors (DPP4i), sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1Ra) with insulin alone for glycemic control and safety outcomes.

Findings: 7 RCT and 3 NRTs were included. Read More

Open Med (Wars) 2022 7;17(1):1203-1215. Epub 2022 Jul 7.

Interdisciplinary Department of Medicine, University of Bari "Aldo Moro," School of Medicine, Bari, 70124 Bari, Italy.

We evaluated the clinical impact, in daily clinical practice, of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) therapies in patients with type 2 diabetes. Data from 500 unselected consecutive patients were retrospectively analyzed. Only those with a full assessment at baseline (T0) and after 3 (T3), 6 (T6), and 12 (T12) months of treatment with SGLT2i or GLP1RA were included in the study ( = 167). Read More

Front Endocrinol (Lausanne) 2022 27;13:895458. Epub 2022 May 27.

Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Aims: This study aimed to assess the impact of different antidiabetic agents on individuals with diabetes and COVID-19.

Methods: We searched PubMed, Web of Science, Embase, and Cochrane Library databases from inception to October 31, 2021 and included seven antidiabetic agents. The data were pooled traditional pairwise meta-analysis and Bayesian network meta-analysis. Read More

BMC Musculoskelet Disord 2022 May 17;23(1):465. Epub 2022 May 17.

Department of Nutrition, Zhujiang Hospital, the Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510000, Guangdong, People's Republic of China.

Background: Diabetes-associated osteoporosis are partly caused by accumulation of advanced glycation endproducts (AGEs). Glucagon-like peptide-1 (GLP-1) has been shown to regulate bone turnover. Here we explore whether GLP-1 receptor agonist (GLP1RA) can have a beneficial effect on bone in diabetes by ameliorating AGEs. Read More

J Diabetes Complications 2022 Jun 30;36(6):108204. Epub 2022 Apr 30.

Kidney Research Institute and Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA, United States of America. Electronic address:

Aims: To determine national prevalence of sodium-glucose contransporter-2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1RA) use among adults with type 2 diabetes mellitus (T2DM).

Methods: We studied adults with T2DM and eGFR ≥ 30 mL/min/1.73 m who participated in the cross-sectional National Health and Nutrition Examination Survey (NHANES), focusing on the 2017-2020 examination cycle, a key time period prior to widespread dissemination of pivotal trial results and corresponding clinical practice guidelines. Read More